60660-75-5

Basic information

• Product Name: (7S,9S)9-ACETYL-7,8,9,10-TETRAHYDRO-6,7,9,11-TETRAHYDROXY-5,12-NAPHTACENEDIONE
• Synonyms: (7S,9S)9-ACETYL-7,8,9,10-TETRAHYDRO-6,7,9,11-TETRAHYDROXY-5,12-NAPHTACENEDIONE;4-demethoxydaunomycinone;(+)-4-DESMETHOXYDAUNOMYCINONE;(7S)-6,7β,9β,11-Tetrahydroxy-9-acetyl-5,7,8,9,10,12-hexahydronaphthacene-5,12-dione;(7S)-9α-Acetyl-7,8,9,10-tetrahydro-6,7β,9,11-tetrahydroxy-5,12-naphthacenedione;(8S,10S)-7,8,9,10-Tetrahydro-6,8,10,11-tetrahydroxy-8-acetyl-5,12-naphthacenedione;Idarubicin aglycone;Idarubicinone
• CAS NO: 60660-75-5
• Molecular Formula: C₂₀H₁₆O₇
• Molecular Weight: 368.33684
• Mol File: 60660-75-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 625.6°C at 760 mmHg
• Flash Point: 346.2°C
• Appearance: /
• Density: 1.626g/cm³
• Vapor Pressure: 1.63E-16mmHg at 25°C
• Refractive Index: 1.742
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (7S,9S)9-ACETYL-7,8,9,10-TETRAHYDRO-6,7,9,11-TETRAHYDROXY-5,12-NAPHTACENEDIONE(CAS DataBase Reference)
• NIST Chemistry Reference: (7S,9S)9-ACETYL-7,8,9,10-TETRAHYDRO-6,7,9,11-TETRAHYDROXY-5,12-NAPHTACENEDIONE(60660-75-5)
• EPA Substance Registry System: (7S,9S)9-ACETYL-7,8,9,10-TETRAHYDRO-6,7,9,11-TETRAHYDROXY-5,12-NAPHTACENEDIONE(60660-75-5)

Safety Data

• Hazardous Substances Data: 60660-75-5(Hazardous Substances Data)

Usage

Uses

(7S,9S)-9-Acetyl-6,7,9,11-tetrahydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione is used in the preparation of anthracycline disaccharides as daunorubicin analogs.

InChI:InChI=1/C20H16O7/c1-8(21)20(27)6-11-13(12(22)7-20)19(26)15-14(18(11)25)16(23)9-4-2-3-5-10(9)17(15)24/h2-5,12,22,25-27H,6-7H2,1H3/t12-,20-/m0/s1

Upstream product

• 84499-10-5 Acetic acid 2,4,12-triacetoxy-2-acetyl-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-5-yl ester 
• 84499-08-1 9-acetoxy-9-acetyl-7-bromo-7,8,9,10-tetrahydro-6,11-diacetoxy-5,12-naphthacenedione 
• 134665-41-1 4-demethoxy-9-deoxydaunomycinone-6,7-acetonide 
• 57852-57-0 idarubicin hydrochloride 

Downstream Products

• 57852-57-0 idarubicin hydrochloride 
• 58957-92-9 idarubicin 
• 82343-11-1 (-)-4'-O-p-Nitrobenzoyl-N-trifluoroacetyl-4-demethoxydaunorubicin 
• 62414-03-3 (7S,9S)-9-acetyl-7-<(3'-amino-2',3',6'-trideoxy-α-L-arabinohexopyranosyl)oxy>-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione 
• 709640-13-1 3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 2-(acetyloxy)-2-phenyl ethanoate 
• 709640-12-0 3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 2-(acetyloxy)-2-phenylethanoate 
• 180182-59-6 C₄₈H₄₂F₃N₃O₁₉ 
• 169317-73-1 C₄₈H₄₂F₃N₃O₁₉ 
• 82343-11-1 4-Nitro-benzoic acid (2S,3R,4S,6R)-6-((1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-2-methyl-4-(2,2,2-trifluoro-acetylamino)-tetrahydro-pyran-3-yl ester 

Relevant articles and documents

Stable lyophilized anthracycline glycosides

The present invention provides lyophilized and stable lyophilized anthracycline glycoside salts, in particular, the hydrochloride salt. Also, the present invention provides methods of stabilizing these anthracycline glycoside salts, and methods for producing stable lyophilized anthracycline glycoside salts, such as for example the antineoplastic compound idarubicin hydrochloride, or the compounds doxorubicin hydrochloride, and epirubicin hydrochloride.

An improved route to 4 demethoxydaunomycinone. A-ring functionalization and resolution studies of tetracyclic precursors

-